Uterine Fibroids: Causes, Symptoms, and Treatment Options

Uterine fibroids are the most common benign tumors of the female reproductive system, affecting an estimated 70–80% of women by age 50 (Office on Women's Health, U.S. Department of Health and Human Services). This page covers how fibroids form, how they are classified by location, the symptoms they produce across different clinical scenarios, and the treatment decision framework clinicians use to guide management. Understanding the full landscape of fibroid care connects directly to broader questions explored at the Women's Health Authority, where reproductive conditions are addressed across all life stages.

Definition and Scope

Uterine fibroids — also called leiomyomas or myomas — are non-cancerous growths composed of smooth muscle cells and fibrous connective tissue that develop within or on the uterine wall. The National Institutes of Health (NIH) classifies fibroids as the leading cause of hysterectomy in the United States, accounting for approximately 200,000 hysterectomies performed annually.

Fibroids vary dramatically in size, from a few millimeters to masses exceeding 20 centimeters in diameter. A single uterus may harbor one fibroid or dozens simultaneously. Most fibroids do not become cancerous; the risk of a fibroid transforming into leiomyosarcoma (uterine cancer) is estimated at less than 1 in 1,000 cases, according to the American College of Obstetricians and Gynecologists (ACOG Practice Bulletin No. 228).

Fibroids are classified by anatomical location into four primary subtypes:

1. Intramural — Located within the muscular wall of the uterus; the most common type.
2. Subserosal — Projecting outward from the outer uterine surface, potentially compressing adjacent organs.
3. Submucosal — Projecting into the uterine cavity; most likely to cause heavy bleeding and fertility disruption.
4. Pedunculated — Attached to the uterus by a stalk, either projecting inward (submucosal pedunculated) or outward (subserosal pedunculated).

This classification directly guides treatment selection, making location as diagnostically significant as size.

How It Works

Fibroid growth is driven primarily by estrogen and progesterone, the hormones that regulate the menstrual cycle. Fibroids contain higher concentrations of hormone receptors than surrounding myometrial tissue, which makes them sensitive to fluctuations across reproductive life stages. Growth typically accelerates during pregnancy — when hormone levels are elevated — and shrinks after menopause, when ovarian hormone production declines.

Genetic factors contribute substantially. Research published through the NIH National Institute of Child Health and Human Development (NICHD) identifies specific chromosomal mutations, including rearrangements in chromosomes 6, 7, 12, and 14, in a significant proportion of fibroid tissue samples. A family history of fibroids increases an individual's risk, and Black women are diagnosed at rates 2–3 times higher than white women, with fibroids typically appearing earlier and growing larger (NIH NICHD).

The mechanism of symptom production depends on location. Submucosal fibroids distort the endometrial cavity, increasing surface area and disrupting the vascular architecture responsible for controlled menstrual shedding — the primary driver of heavy menstrual bleeding. Subserosal fibroids exert pressure on the bladder or rectum, producing urinary frequency or constipation. Intramural fibroids may cause both, depending on size and direction of growth. Pedunculated fibroids carry a distinct risk of torsion, which produces acute pelvic pain requiring prompt clinical evaluation.

Imaging via pelvic ultrasound — the standard first-line diagnostic tool per ACOG — confirms fibroid presence, number, location, and size. MRI provides superior soft-tissue characterization when surgical planning or differentiation from adenomyosis is required.

Common Scenarios

Fibroid presentations cluster into recognizable clinical patterns. Awareness of these scenarios supports informed conversation between patients and clinicians. The regulatory context for women's health governs how fibroid screening, diagnosis, and treatment are covered under federal and state insurance frameworks.

Heavy Menstrual Bleeding (Menorrhagia)
The most prevalent fibroid symptom, particularly associated with submucosal and intramural types. Heavy bleeding can lead to iron-deficiency anemia; the CDC defines anemia as hemoglobin below 12 g/dL in non-pregnant women (CDC Nutrition, Physical Activity, and Obesity). Fatigue, shortness of breath, and reduced exercise tolerance signal anemia severity.

Pelvic Pressure and Pain
Subserosal fibroids larger than 5 cm frequently compress the bladder, causing urinary urgency or frequency without infection. Rectal pressure from posterior fibroids may produce incomplete evacuation. Chronic pelvic pain affects quality of life and may be confused with endometriosis or polycystic ovary syndrome (PCOS), necessitating differential diagnosis.

Fertility and Pregnancy Complications
Submucosal fibroids demonstrably impair implantation rates. ACOG notes that myomectomy — fibroid removal with uterine preservation — improves pregnancy outcomes in women with submucosal fibroids causing cavity distortion. Fibroids during pregnancy carry elevated risks of preterm labor, placental abruption, and cesarean delivery.

Asymptomatic Fibroids
A substantial proportion of fibroids produce no symptoms and are discovered incidentally during pelvic ultrasound or routine examination. Asymptomatic fibroids in premenopausal women without fertility concerns typically require monitoring rather than intervention.

Decision Boundaries

Treatment selection is determined by a structured framework incorporating symptom severity, fibroid location and number, reproductive goals, proximity to menopause, and patient preference. No single approach is universally appropriate.

Watchful Waiting
Indicated for asymptomatic fibroids or when symptoms are mild and manageable. Serial ultrasound monitoring — typically every 6–12 months — tracks growth trajectory.

Medical Management
Hormonal therapies modulate the estrogen-progesterone environment to reduce fibroid size or control bleeding. Options include:
- GnRH agonists (e.g., leuprolide): Reduce fibroid volume by up to 50% in 3–6 months but cause menopausal side effects and bone density loss with prolonged use (FDA-approved labeling).
- GnRH antagonists (e.g., elagolix with add-back therapy): FDA-approved for uterine fibroid-associated heavy menstrual bleeding under the brand name Oriahnn, offering shorter onset than agonists.
- Levonorgestrel IUD: Controls bleeding without reducing fibroid size; most effective for small submucosal or intramural fibroids without significant cavity distortion.
- Tranexamic acid: A non-hormonal antifibrinolytic agent FDA-approved for heavy menstrual bleeding; reduces blood loss per cycle without affecting fibroid volume.

Minimally Invasive Procedures
- Uterine Fibroid Embolization (UFE): An interventional radiology procedure that occludes uterine arteries supplying fibroids, causing infarction and volume reduction of approximately 40–60% (Society of Interventional Radiology). Not recommended for women planning pregnancy.
- Endometrial Ablation: Destroys the uterine lining to reduce bleeding; suitable only for women who have completed childbearing and is not a fibroid-specific treatment.
- MRI-guided Focused Ultrasound (MRgFUS): FDA-cleared for symptomatic fibroid ablation using focused ultrasound energy without incision; efficacy is highest for isolated, accessible fibroids.

Surgical Options
- Myomectomy: Surgical removal of fibroids with uterine preservation. Available via open laparotomy, laparoscopy, or hysteroscopy depending on fibroid location. Hysteroscopic myomectomy is the preferred approach for submucosal fibroids.
- Hysterectomy: Complete removal of the uterus; the only permanent cure for fibroids. Eliminates recurrence by definition but forecloses fertility. Route (vaginal, laparoscopic, abdominal) depends on uterine size, fibroid number, and surgical history.

Comparison: Myomectomy vs. Hysterectomy

The choice between these approaches is governed by ACOG Practice Bulletin No. 228, which frames shared decision-making as the clinical standard. Fibroid management intersects with [pelvic floor health](/p

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)